| abstract |
The present invention relates to a genetically modified human stem cell, in which said human stem cell comprises an exogenous nucleic acid comprising a region encoding a fusion protein comprising a mutant human cytochrome P450 2B6 protein (CYP2B6*) of SEQ ID No. 1, or a variant or fragment thereof, and an NADPH-cytochrome P450 reductase protein of SEQ ID No. 2, or a variant or fragment thereof, functionally bonded to a promoter, said exogenous nucleic acid having been integrated into one of the safe harbor genes of said human stem cell. The invention also relates to the use of said cell for the treatment of cancer and/or cancer recurrences and/or associated metastases, in particular solid tumours, and in particular hepatocellular carcinomas and/or associated metastases. |